Quick Take
Generation Bio (GBIO) intends to raise $126 million from the sale of its common stock in a U.S. IPO, per an amended registration statement.
The company is a pre clinical developer of genetic treatments for liver and retinal diseases.
GBIO is an ultra early stage biopharma and the IPO appears more suited to long-term oriented institutional venture investors rather than individuals.
Company & Technology
Cambridge, Massachusetts-based Gen Bio was founded to create a non-viral gene therapy pipeline to deliver genetic payloads for large or multiple genes to various tissues in